Improvement in verbal memory following SSRI augmentation of antipsychotic treatment is associated with changes in the expression of mRNA encoding for the GABA-A receptor and BDNF in PMC of schizophrenic patients

International Clinical Psychopharmacology

Volumn 30, Issue 3, 2015, Pages 158-166

  Silver, Henry ^a   Mandiuk, Nina ^a   Einoch, Reef ^a,b   Susser, Ehud ^a   Danovich, Lena ^a   Bilker, Warren ^c   Youdim, Moussa ^b   Weinreb, Orly ^a,b  

^a SHA'AR MENASHE MENTAL HEALTH CENTER   (Israel)

^b TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Cognition; Hippocampus; Synaptic plasticity

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR BETA3; BRAIN DERIVED NEUROTROPHIC FACTOR; FLUVOXAMINE; MESSENGER RNA; OLANZAPINE; QUETIAPINE; RISPERIDONE; 4 AMINOBUTYRIC ACID A RECEPTOR; BRAIN-DERIVED NEUROTROPHIC FACTOR, HUMAN; NEUROLEPTIC AGENT; SEROTONIN UPTAKE INHIBITOR;

ADD ON THERAPY; ADULT; ARTICLE; ASSOCIATIVE MEMORY; BLOOD SAMPLING; CLINICAL ARTICLE; COGNITION; DRUG WITHDRAWAL; EXECUTIVE FUNCTION; EXPLICIT MEMORY; GENE EXPRESSION; GENETIC CODE; HEBEPHRENIA; HUMAN; NEGATIVE SYNDROME; NERVE CELL PLASTICITY; PARANOID SCHIZOPHRENIA; PERIPHERAL BLOOD MONONUCLEAR CELL; POSITIVE SYNDROME; PRIORITY JOURNAL; PSYCHOMOTOR ACTIVITY; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; RECOGNITION; RESIDUAL SCHIZOPHRENIA; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCHIZOPHRENIA; SEXUAL DYSFUNCTION; TREATMENT DURATION; VERBAL MEMORY; VISUAL ORIENTATION; WORKING MEMORY; BIOSYNTHESIS; BLOOD; DRUG COMBINATION; DRUG EFFECTS; FEMALE; GENE EXPRESSION REGULATION; LEARNING; MALE; MEMORY; METABOLISM; MONONUCLEAR CELL; PHYSIOLOGY; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; ANTIPSYCHOTIC AGENTS; BRAIN-DERIVED NEUROTROPHIC FACTOR; DRUG THERAPY, COMBINATION; FEMALE; FLUVOXAMINE; GENE EXPRESSION REGULATION; HUMANS; LEUKOCYTES, MONONUCLEAR; MALE; MEMORY; RECEPTORS, GABA-A; RNA, MESSENGER; SCHIZOPHRENIA; SEROTONIN UPTAKE INHIBITORS; TREATMENT OUTCOME; VERBAL LEARNING; YOUNG ADULT;

EID: 84927136067     PISSN: 02681315     EISSN: 14735857     Source Type: Journal    
DOI: 10.1097/YIC.0000000000000070     Document Type: Article

References (52)

1. Addington D, Addington J, Maticka-Tyndale E (1993). Assessing depression in schizophrenia: the Calgary Depression Scale. Br J Psychiatry Suppl 163 (Suppl 22):39-44.
2. Aleman A, Hijman R, de Haan EH, Kahn RS (1999). Memory impairment in schizophrenia: a meta-analysis. Am J Psychiatry 156:1358-1366.
3. Andreasen NC (1984). Scale for the assessment of negative symptoms (SANS). Iowa City: University of Iowa.
4. Andreasen NC (1990). Positive and negative symptoms: historical and conceptual aspects. Mod Probl Pharmacopsychiatry 24:1-42.
5. Arnsten AF (2011). Prefrontal cortical network connections: key site of vulnerability in stress and schizophrenia. Int J Dev Neurosci 29:215-223.
6. Badre D, Hoffman J, Cooney JW, D'Esposito M (2009). Hierarchical cognitive control deficits following damage to the human frontal lobe. Nat Neurosci 12:515-522.
7. Bakeman R (2005). Recommended effect size statistics for repeated measures designs. Behav Res Methods 37:379-384.
8. Bartels C, Wegrzyn M, Wiedl A, Ackermann V, Ehrenreich H (2010). Practice effects in healthy adults: a longitudinal study on frequent repetitive cognitive testing. BMC Neurosci 11:118.
9. Chertkow Y, Weinreb O, Youdim MB, Silver H (2009). Molecular mechanisms underlying synergistic effects of SSRI-antipsychotic augmentation in treatment of negative symptoms in schizophrenia. J Neural Transm 116:1529-1541.
10. Davidson M, Galderisi S, Weiser M, Werbeloff N, Fleischhacker WW, Keefe RS, et al. (2009). Cognitive effects of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: a randomized, open-label clinical trial (EUFEST). Am J Psychiatry 166:675-682.
11. Deng W, Aimone JB, Gage FH (2010). New neurons and new memories: how does adult hippocampal neurogenesis affect learning and memory? Nat Rev Neurosci 11:339-350.
12. Einoch R, Weinreb O, Youdim MBH, Silver H (2014). The involvement of CREB and GABA-A receptor in SSRI-antipsychotic therapy of negative symptoms in schizophrenia. FENS conference. Milan, Italy; July 2014.
13. Gonzalez-Burgos G, Fish KN, Lewis DA (2011). GABA neuron alterations, cortical circuit dysfunction and cognitive deficits in schizophrenia. Neural Plast 2011:723184.
14. Green MF (1996). What are the functional consequences of neurocognitive deficits in schizophrenia? Am J Psychiatry 153:321-330.
15. Guy W (1976). Abnormal involuntary movement scale (AIMS) ECDEU assessment manual for psychopharmacology. Rockville, MD: National Institute of Mental Health. pp. 534-537.
16. Han DH, Park DB, Choi TY, Joo SY, Lee MK, Park BR, et al. (2008). Effects of brain-derived neurotrophic factor-catecholamine-O-methyltransferase gene interaction on schizophrenic symptoms. Neuroreport 19:1155-1158.
17. Heinrichs RW, Zakzanis KK (1998). Neurocognitive deficit in schizophrenia: a quantitative review of the evidence. Neuropsychology 12:426-445.
18. Hiemke C, Peled A, Jabarin M, Hadjez J, Weigmann H, Hartter S, et al. (2002). Fluvoxamine augmentation of olanzapine in chronic schizophrenia: pharmacokinetic interactions and clinical effects. J Clin Psychopharmacol 22:502-506.
19. Hill SK, Reilly JL, Keefe RS, Gold JM, Bishop JR, Gershon ES, et al. (2013). Neuropsychological impairments in schizophrenia and psychotic bipolar disorder: Findings from the Bipolar and Schizophrenia Network on Intermediate Phenotypes (B-SNIP) study. Am J Psychiatry 170:1275-1284.
20. Joshi S, Kapur J (2009). Slow intracellular accumulation of GABA(A) receptor delta subunit is modulated by brain-derived neurotrophic factor. Neuroscience 164:507-519.
21. Jovanovic JN, Thomas P, Kittler JT, Smart TG, Moss SJ (2004). Brain-derived neurotrophic factor modulates fast synaptic inhibition by regulating GABA(A) receptor phosphorylation, activity, and cell-surface stability. J Neurosci 24:522-530.
22. Kanematsu T, Yasunaga A, Mizoguchi Y, Kuratani A, Kittler JT, Jovanovic JN, et al. (2006). Modulation of GABA(A) receptor phosphorylation and membrane trafficking by phospholipase C-related inactive protein/protein phosphatase 1 and 2A signaling complex underlying brain-derived neurotrophic factordependent regulation of GABAergic inhibition. J Biol Chem 281:22180-22189.
23. Keefe RE, Bilder RM, Davis SM, Harvey PD, Palmer BW, Gold JM, et al. (2007). Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE trial. Arch Gen Psychiatry 64:633-647.
24. Keefe RS, Fox KH, Harvey PD, Cucchiaro J, Siu C, Loebel A (2011). Characteristics of the MATRICS consensus cognitive battery in a 29-site antipsychotic schizophrenia clinical trial. Schizophr Res 125 (2-3):161-168.
25. Kim DH, Kim JM, Park SJ, Cai M, Liu X, Lee S, et al. (2012). GABA(A) receptor blockade enhances memory consolidation by increasing hippocampal BDNF levels. Neuropsychopharmacology 37:422-433.
26. Kuczewski N, Fuchs C, Ferrand N, Jovanovic JN, Gaiarsa JL, Porcher C (2011). Mechanism of GABAB receptor-induced BDNF secretion and promotion of GABAA receptor membrane expression. J Neurochem 118 :533-545.
27. Lett TA, Voineskos AN, Kennedy JL, Levine B, Daskalakis ZJ (2014). Treating working memory deficits in schizophrenia: a review of the neurobiology. Biol Psychiatry 75:361-370.
28. Lewis DA, Moghaddam B (2006). Cognitive dysfunction in schizophrenia: convergence of gamma-aminobutyric acid and glutamate alterations. Arch Neurol 63:1372-1376.
29. Lewis DA, Hashimoto T, Volk DW (2005). Cortical inhibitory neurons and schizophrenia. Nat Rev Neurosci 6:312-324.
30. Mandelman SD, Grigorenko EL (2012). BDNF Val66Met and cognition: all, none, or some? A meta-analysis of the genetic association. Genes Brain Behav 11:127-136.
31. Moghaddam B, Homayoun H (2008). Divergent plasticity of prefrontal cortex networks. Neuropsychopharmacology 33:42-55.
32. Nieto R, Kukuljan M, Silva H (2013). BDNF and schizophrenia: from neurodevelopment to neuronal plasticity, learning, and memory. Front Psychiatry 4:45.
33. Niitsu T, Shirayama Y, Matsuzawa D, Hasegawa T, Kanahara N, Hashimoto T, et al. (2011). Associations of serum brain-derived neurotrophic factor with cognitive impairments and negative symptoms in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 35:1836-1840.
34. Niitsu T, Fujisaki M, Shiina A, Yoshida T, Hasegawa T, Kanahara N, et al. (2012). A randomized, double-blind, placebo-controlled trial of fluvoxamine in patients with schizophrenia: a preliminary study. J Clin Psychopharmacol 32:593-601.
35. Pan W, Banks WA, Fasold MB, Bluth J, Kastin AJ (1998). Transport of brain-derived neurotrophic factor across the blood-brain barrier. Neuropharmacology 37:1553-1561.
36. Papaleo F, Lipska BK, Weinberger DR (2012). Mouse models of genetic effects on cognition: relevance to schizophrenia. Neuropharmacology 62:1204-1220.
37. Pillai A, Kale A, Joshi S, Naphade N, Raju MS, Nasrallah H, Mahadik SP (2010). Decreased BDNF levels in CSF of drug-naive first-episode psychotic subjects: correlation with plasma BDNF and psychopathology. Int J Neuropsychopharmacol 13:535-539.
38. Robbins TW, Arnsten AF (2009). The neuropsychopharmacology of fronto-executive function: monoaminergic modulation. Annu Rev Neurosci 32:267-287.
39. Sanchez-Huertas C, Rico B (2011). CREB-dependent regulation of GAD65 transcription by BDNF/TrkB in cortical interneurons. Cereb Cortex 21:777-788.
40. Silver H, Nassar A (1992). Fluvoxamine improves negative symptoms in treated chronic schizophrenia: an add-on double-blind, placebo-controlled study. Biol Psychiatry 31:698-704.
41. Silver H, Shmugliakov N (1998). Augmentation with fluvoxamine but not maprotiline improves negative symptoms in treated schizophrenia: evidence for a specific serotonergic effect from a double-blind study. J Clin Psychopharmacol 18:208-211.
42. Silver H, Bilker WB (2013). Add-on fluvoxamine and negative symptoms of schizophrenia: analysis of data from augmentation studies in a single center. J Clin Psychopharmacol 33 :710-711.
43. Silver H, Barash I, Aharon N, Kaplan A, Poyurovsky M (2000). Fluvoxamine augmentation of antipsychotics improves negative symptoms in psychotic chronic schizophrenic patients: a placebo-controlled study. Int Clin Psychopharmacol 15:257-261.
44. Silver H, Feldman P, Bilker W, Gur RC (2003). Working memory deficit as a core neuropsychological dysfunction in schizophrenia. Am J Psychiatry 160:1809-1816.
45. Silver H, Chertkow Y, Weinreb O, Danovich L, Youdim M (2009). Multifunctional pharmacotherapy: what can we learn from study of selective serotonin reuptake inhibitor augmentation of antipsychotics in negative-symptom schizophrenia? Neurotherapeutics 6:86-93.
46. Silver H, Susser E, Danovich L, Bilker W, Youdim M, Goldin V, Weinreb O (2010). SSRI augmentation of antipsychotic alters expression of GABAA receptor and related genes in PMC of schizophrenia patients. Int J Neuropsychopharmacol 14:573-584.
47. Silver H, Einoch R, Youdim M, Weinreb O (2013). The role of GABA-A receptor in the synergism between SSRI and antipsychotic in schizophrenia; implications for antipsychotic modes of actions. Curr Med Chem 20:363-370.
48. Simpson GM, Angus JW (1970). A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 212:11-19.
49. Tan HY, Callicott JH, Weinberger DR. Prefrontal cognitive systems in schizophrenia: towards human genetic brain mechanisms. Cogn Neuropsychiatry 2009; 14 (4-5):277-298.
50. Weinberger DR, Egan MF, Bertolino A, Callicott JH, Mattay VS, Lipska BK, et al. (2001). Prefrontal neurons and the genetics of schizophrenia. Biol Psychiatry 50:825-844.
51. Woo NH, Lu B (2006). Regulation of cortical interneurons by neurotrophins: from development to cognitive disorders. Neuroscientist 12:43-56.
52. Xiu MH, Hui L, Dang YF, Hou TD, Zhang CX, Zheng YL, et al. (2009). Decreased serum BDNF levels in chronic institutionalized schizophrenia on long-term treatment with typical and atypical antipsychotics. Prog Neuropsychopharmacol Biol Psychiatry 33:1508-1512.